Your Weight Loss Medication Might Be Fighting Your Cancer, Too

Tough enough to rope with pink

Wegovy and Zepbound are all the rage in the media right now because they work for weight loss. We prescribe Ozempic and Mounjaro because they work for diabetes. But a study just dropped in JAMA Network Open that made me sit up straight in my chair — and I want every woman who takes one of these medications to know about it.

Breast cancer is the most common cancer in women in the United States, and if you have obesity or type 2 diabetes when you are diagnosed, your odds of surviving that cancer — and of it not coming back — are measurably worse. Obesity and metabolic disease are not just weight problems. They are cancer prognostic factors.

Researchers at Virginia Commonwealth University pulled data from 841,831 women with breast cancer across 68 health care organizations — one of the largest datasets ever assembled for a question like this. They wanted to know: did it matter whether a woman with breast cancer was also taking a GLP-1 medication like semaglutide or tirzepatide?

They split patients into groups — women with obesity, women with type 2 diabetes — and carefully matched them so the comparison was apples to apples. Then they tracked survival and cancer recurrence for up to ten years.

In women with breast cancer and obesity, those taking a GLP-1 medication had dramatically better outcomes over ten years compared to those not taking one. We're talking a 65% lower risk of death from any cause, and a 56% lower risk of cancer recurrence.

Then there's the diabetes group. Women with breast cancer and type 2 diabetes who were on a GLP-1 medication had a 91% lower hazard of death compared to women on insulin or metformin. The ten-year survival probability for GLP-1 users with obesity was 96%, compared to 88.6% for non-users. That is not a rounding error. That is eight years later and people are still alive who otherwise might not be.

The researchers used propensity score matching — essentially a statistical method to make sure the groups were as similar as possible before comparing them — and the associations held up across every analysis they ran.

This study is looking back at what happened in a group of people, so it doesn't tell us what caused the effect. All it can show us is an association, but this is a really large result and will drive a lot more study in the future. We have to give the science time to figure out how these medications might be protective, but there are some good theories about what is happening.

Obesity creates an inflammatory, insulin-resistant environment in the body. Tumor cells love that environment. Fat cells, especially in the abdomen, produces estrogen, which feeds hormone-receptor-positive breast cancers, the most common kind. When obesity goes down, that fuel source gets cut. GLP-1 medications are extraordinarily effective at reducing body fat, and that may translate directly into a less hospitable environment for cancer to grow or return.

It also gets nerdier than that. Preclinical studies (the ones with nerds at lab benches, not studies in humans) have suggested that GLP-1 receptor agonists may directly inhibit tumor growth in certain cancers, including breast cancer. GLP-1 receptors have been found on some cancer cells, and activating them may trigger pathways that slow proliferation. This is still early science, but it is a compelling thread researchers are actively pulling.

High insulin levels are a known driver of cancer cell growth. GLP-1 medications dramatically improve insulin sensitivity. It is increasingly plausible that quieting that insulin environment does something meaningful for cancer biology, not just for blood sugar.

This study does not tell us that GLP1s cure cancer, or save lives, or even impact cancer at all. This was a retrospective study, meaning researchers looked back at medical records, not forward in a controlled experiment. By the nature of this type of study, we cannot say with certainty that the medication caused better outcomes. Women who were prescribed GLP-1 medications may differ in ways the researchers could not fully account for. The authors themselves call for randomized clinical trials to confirm these findings. We are not there yet. What we have is a very large, very intriguing association that demands further investigation.

If you have been on the fence about starting, and you have obesity or metabolic disease, this adds another layer to an already compelling conversation. If you are a breast cancer survivor or are high risk for other reasons like family history or military/occupational exposures, bring this up with your oncologist. Treatment decisions for cancer are nuanced and should always involve your full care team.

If you are someone who has been told to just lose some weight and have never been offered real help doing it, this is exactly the kind of science that makes me furious on your behalf. Managing obesity is managing metabolic disease. Managing metabolic disease may, it turns out, be managing cancer risk. These are not separate problems.

GLP-1 medications were already remarkable. They have shown benefits for weight, diabetes, heart disease, kidney disease, and sleep apnea. Adding to that impressive list of good things, in a dataset of nearly a million women, there is a striking association with better breast cancer survival and lower recurrence rates.

We are not prescribing these medications as cancer treatment. That is not what this says, and we need the randomized trials before anyone draws that line. We are prescribing them to treat obesity and metabolic disease, and those are real, serious conditions with real, serious downstream consequences — including consequences for cancer prognosis.

The science is moving fast. I will keep watching it and keep bringing it to you. That is the whole point of Talk Nerdy to Me.

TL;DR on the Study (Link to full study)

The basics: A study published in JAMA Network Open (May 2026) looked at whether women with breast cancer who were taking a GLP-1 medication — like semaglutide or tirzepatide — had better outcomes than those who weren't. Spoiler: the difference was significant.

Who was in the study: 841,831 women diagnosed with stages I–III breast cancer across 68 U.S. health care organizations, diagnosed between 2006 and 2023.

What they did: Researchers used propensity score matching — a statistical method to make the comparison groups as similar as possible — then tracked all-cause mortality and cancer recurrence for up to ten years. Three comparisons were made: GLP-1 users versus non-users in women with obesity, GLP-1 users versus insulin or metformin users in women with type 2 diabetes, and GLP-1 users versus SGLT2 inhibitor users in women with type 2 diabetes.

The results: Women with obesity on a GLP-1 had a 65% lower risk of death and a 56% lower risk of cancer recurrence compared to non-users. Women with type 2 diabetes on a GLP-1 had a 91% lower risk of death compared to those on insulin or metformin. Ten-year survival probability was 96% in the GLP-1 group versus 88.6% in non-users.

Why it matters: Obesity and diabetes are already known to worsen breast cancer outcomes. If the medications we use to treat those conditions also improve cancer survival, that changes the risk-benefit conversation significantly — especially for women who have been on the fence about starting treatment.

The catch: This was a retrospective study, meaning researchers looked backward at medical records rather than running a controlled experiment. We cannot say the medication caused the better outcomes — only that there is a strong association. The authors are calling for randomized controlled trials to confirm. We are not at "GLP-1s treat cancer" yet. We are at "this is too large and too consistent to ignore."

How it probably works: GLP-1 medications reduce body fat, lower insulin levels, and decrease inflammation — all of which make a less hospitable environment for tumor growth. There is also early lab evidence that GLP-1 receptors exist on some cancer cells directly, and activating them may slow proliferation. The full picture is still being worked out.